The series of TAXUS studies demonstrated the safety and efficacy of both slow- and moderate-release formulations of the paclitaxel-eluting TAXUS stent (Boston Scientific; Natick, Massachusetts) in ...

Pooled-analysis of five clinical trials found that patients requiring treatment with two or more overlapping stents for long artery blockages experienced better outcomes when receiving CYPHER ...

Overlapping of bioresorbable vascular scaffolds was linked to increased rates of periprocedural MI but no immediate or long-term effects on cardiac death, target lesion revascularization or stent ...

PHOENIX, AZ—In patients with diffuse CAD, a next-generation, longer-length stent may eliminate the need for multiple overlapping devices for treating long, continuous plaques, according to results ...

Please provide your email address to receive an email when new articles are posted on . A novel stent for treating long coronary lesions met its primary performance goal at 1 year. The 48-mm stent was ...

BLOOMINGTON, Indiana — Following the advice of its advisory panel, the Food and Drug Administration has approved the Zilver PTX paclitaxel-eluting peripheral stent (Cook Medical, Bloomington, IN) for ...

PHOENIX -- The novel, next-generation Xience drug-eluting stent (DES) with a 48-mm length met the performance bar with a particularly low restenosis rate, the SPIRIT 48 trial showed. The Xience ...

Charleston (W.Va.) Area Medical Center, an affiliate of Vandalia Health, in collaboration with the CAMC Clinical Trials Center, is the first site in the world activated for the Bioflow-48 stent study ...

BUFFALO, N.Y. -- The old adage about two being better than one doesn't necessarily apply to brain surgery. That's according to a study performed by University at Buffalo engineers that used high ...

Johnson & Johnson aims to seal a purchase of Guidant Corp. without immediately jettisoning the medical device maker's stent operations, sources familiar with the situation said on Thursday. A deal ...